Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.76
ALKS's Cash to Debt is ranked higher than
61% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. ALKS: 1.76 )
ALKS' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 1.76

Equity to Asset 0.73
ALKS's Equity to Asset is ranked higher than
78% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALKS: 0.73 )
ALKS' s 10-Year Equity to Asset Range
Min: -0.02   Max: 0.87
Current: 0.73

-0.02
0.87
F-Score: 2
Z-Score: 11.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -14.08
ALKS's Operating margin (%) is ranked higher than
81% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. ALKS: -14.08 )
ALKS' s 10-Year Operating margin (%) Range
Min: -331.3   Max: 41.29
Current: -14.08

-331.3
41.29
Net-margin (%) -4.86
ALKS's Net-margin (%) is ranked higher than
82% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. ALKS: -4.86 )
ALKS' s 10-Year Net-margin (%) Range
Min: -296.89   Max: 69.37
Current: -4.86

-296.89
69.37
ROE (%) -2.77
ALKS's ROE (%) is ranked higher than
84% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ALKS: -2.77 )
ALKS' s 10-Year ROE (%) Range
Min: -288.88   Max: 65.64
Current: -2.77

-288.88
65.64
ROA (%) -2.02
ALKS's ROA (%) is ranked higher than
85% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ALKS: -2.02 )
ALKS' s 10-Year ROA (%) Range
Min: -38.95   Max: 27.26
Current: -2.02

-38.95
27.26
ROC (Joel Greenblatt) (%) -27.04
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. ALKS: -27.04 )
ALKS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -301.66   Max: 104.64
Current: -27.04

-301.66
104.64
Revenue Growth (3Y)(%) 31.30
ALKS's Revenue Growth (3Y)(%) is ranked higher than
93% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ALKS: 31.30 )
ALKS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22   Max: 69.1
Current: 31.3

-22
69.1
EPS Growth (3Y)(%) -20.60
ALKS's EPS Growth (3Y)(%) is ranked higher than
68% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ALKS: -20.60 )
ALKS' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.6   Max: 224
Current: -20.6

-20.6
224
» ALKS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ALKS Guru Trades in Q1 2014

Steven Cohen 5,591 sh (New)
John Burbank 4,651 sh (New)
Vanguard Health Care Fund 5,180,238 sh (+41.07%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 29,851 sh (-6.28%)
Pioneer Investments 180,753 sh (-15.16%)
Jim Simons 53,310 sh (-89.46%)
» More
Q2 2014

ALKS Guru Trades in Q2 2014

Ken Fisher 55,309 sh (New)
Jim Simons 214,686 sh (+302.71%)
Vanguard Health Care Fund 6,135,913 sh (+18.45%)
Murray Stahl 25,000 sh (unchged)
John Burbank Sold Out
Pioneer Investments 175,517 sh (-2.90%)
Jeff Auxier 28,851 sh (-3.35%)
» More
Q3 2014

ALKS Guru Trades in Q3 2014

Ken Fisher 97,264 sh (+75.86%)
Vanguard Health Care Fund 6,223,083 sh (+1.42%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 28,851 sh (unchged)
Pioneer Investments 292,728 sh (unchged)
Jim Simons 155,786 sh (-27.44%)
» More
Q4 2014

ALKS Guru Trades in Q4 2014

Ken Fisher 107,164 sh (+10.18%)
Vanguard Health Care Fund 6,226,383 sh (+0.05%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 27,851 sh (-3.47%)
Pioneer Investments 281,576 sh (-3.81%)
Jim Simons 63,986 sh (-58.93%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 72.46
ALKS's Forward P/E is ranked higher than
86% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: 72.46 )
N/A
P/B 7.00
ALKS's P/B is ranked higher than
63% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. ALKS: 7.00 )
ALKS' s 10-Year P/B Range
Min: 1.66   Max: 379.8
Current: 7

1.66
379.8
P/S 14.78
ALKS's P/S is ranked higher than
69% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. ALKS: 14.78 )
ALKS' s 10-Year P/S Range
Min: 2.19   Max: 35.3
Current: 14.78

2.19
35.3
POCF 840.00
ALKS's POCF is ranked higher than
87% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: 840.00 )
ALKS' s 10-Year POCF Range
Min: 8.73   Max: 915.5
Current: 840

8.73
915.5
EV-to-EBIT -111.05
ALKS's EV-to-EBIT is ranked higher than
83% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: -111.05 )
ALKS' s 10-Year EV-to-EBIT Range
Min: -1059.6   Max: 628
Current: -111.05

-1059.6
628
Current Ratio 6.71
ALKS's Current Ratio is ranked higher than
81% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ALKS: 6.71 )
ALKS' s 10-Year Current Ratio Range
Min: 2.74   Max: 15.38
Current: 6.71

2.74
15.38
Quick Ratio 6.32
ALKS's Quick Ratio is ranked higher than
81% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. ALKS: 6.32 )
ALKS' s 10-Year Quick Ratio Range
Min: 2.69   Max: 15.38
Current: 6.32

2.69
15.38
Days Inventory 88.97
ALKS's Days Inventory is ranked higher than
91% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: 88.97 )
ALKS' s 10-Year Days Inventory Range
Min: 43.09   Max: 166.33
Current: 88.97

43.09
166.33
Days Sales Outstanding 89.39
ALKS's Days Sales Outstanding is ranked higher than
77% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 112.01 vs. ALKS: 89.39 )
ALKS' s 10-Year Days Sales Outstanding Range
Min: 27.46   Max: 139.47
Current: 89.39

27.46
139.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 87.40
ALKS's Price/Net Cash is ranked higher than
60% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. ALKS: 87.40 )
ALKS' s 10-Year Price/Net Cash Range
Min: 3.7   Max: 104.47
Current: 87.4

3.7
104.47
Price/Net Current Asset Value 37.70
ALKS's Price/Net Current Asset Value is ranked higher than
63% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. ALKS: 37.70 )
ALKS' s 10-Year Price/Net Current Asset Value Range
Min: 3.27   Max: 43.88
Current: 37.7

3.27
43.88
Price/Tangible Book 11.20
ALKS's Price/Tangible Book is ranked higher than
58% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. ALKS: 11.20 )
ALKS' s 10-Year Price/Tangible Book Range
Min: 1.76   Max: 336
Current: 11.2

1.76
336
Price/DCF (Projected) 7.40
ALKS's Price/DCF (Projected) is ranked higher than
90% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALKS: 7.40 )
ALKS' s 10-Year Price/DCF (Projected) Range
Min: 2.31   Max: 6.86
Current: 7.4

2.31
6.86
Price/Median PS Value 2.10
ALKS's Price/Median PS Value is ranked higher than
72% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ALKS: 2.10 )
ALKS' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 14.14
Current: 2.1

0.41
14.14
Earnings Yield (Greenblatt) -0.90
ALKS's Earnings Yield (Greenblatt) is ranked higher than
82% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ALKS: -0.90 )
ALKS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.9   Max: 27.9
Current: -0.9

-0.9
27.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company. It is engaged in developing, manufacturing and commercializing medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious diseases. It has a diversified portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression. The Company relies on its manufacturing facility in Wilmington, Ohio for the manufacture of RISPERDAL CONSTA, VIVITROL, polymer for BYDUREON and some of its product candidates.
» More Articles for ALKS

Headlines

Articles On GuruFocus.com
wait for positive ea Apr 06 2013 
comment on ALKS Mar 09 2013 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 09 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 06 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
Alkermes plc -- Moody's affirms Alkermes' Ba3 ratings; changes outlook to stable Mar 23 2015
Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on... Mar 23 2015
Alkermes Streamlines Operations, Revises 2015 Guidance - Analyst Blog Mar 10 2015
Alkermes to Sell Plant to Recro Pharma Mar 09 2015
Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Mar 09 2015
ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Mar 09 2015
Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Mar 09 2015
Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc. Mar 09 2015
Cramer: Best of biotech Mar 04 2015
Alkermes Intends to Add New Candidate to its Pipeline - Analyst Blog Mar 03 2015
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 03 2015
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 03 2015
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference Mar 03 2015
ALKERMES PLC. Financials Mar 03 2015
Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation,... Mar 02 2015
Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation,... Mar 02 2015
Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation,... Mar 02 2015
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK